268 related articles for article (PubMed ID: 25454484)
21. Early prediction of treatment response to high-dose salvage chemotherapy in patients with relapsed germ cell cancer using [(18)F]FDG PET.
Bokemeyer C; Kollmannsberger C; Oechsle K; Dohmen BM; Pfannenberg A; Claussen CD; Bares R; Kanz L
Br J Cancer; 2002 Feb; 86(4):506-11. PubMed ID: 11870528
[TBL] [Abstract][Full Text] [Related]
22. Diagnostic performance of fluorine-18-fluorodeoxyglucose positron emission tomography in the postchemotherapy management of patients with seminoma: systematic review and meta-analysis.
Treglia G; Sadeghi R; Annunziata S; Caldarella C; Bertagna F; Giovanella L
Biomed Res Int; 2014; 2014():852681. PubMed ID: 24963486
[TBL] [Abstract][Full Text] [Related]
23. Is percent seminoma associated with intraoperative morbidity during post-chemotherapy RPLND?
Russell CM; Sharma P; Agarwal G; Fisher JS; Richard GJ; Spiess PE; Pow-Sang JM; Poch MA; Sexton WJ
Can J Urol; 2016 Feb; 23(1):8127-34. PubMed ID: 26892052
[TBL] [Abstract][Full Text] [Related]
24. Fluorodeoxyglucose positron emission tomography in the evaluation of germ cell tumours at relapse.
Hain SF; O'Doherty MJ; Timothy AR; Leslie MD; Harper PG; Huddart RA
Br J Cancer; 2000 Oct; 83(7):863-9. PubMed ID: 10970686
[TBL] [Abstract][Full Text] [Related]
25. Contemporary management of postchemotherapy testis cancer.
Daneshmand S; Albers P; Fosså SD; Heidenreich A; Kollmannsberger C; Krege S; Nichols C; Oldenburg J; Wood L
Eur Urol; 2012 Nov; 62(5):867-76. PubMed ID: 22938868
[TBL] [Abstract][Full Text] [Related]
26. Postchemotherapy retroperitoneal lymph node dissection in advanced testicular cancer: radical or modified template resection.
Heidenreich A; Pfister D; Witthuhn R; Thüer D; Albers P
Eur Urol; 2009 Jan; 55(1):217-24. PubMed ID: 18926622
[TBL] [Abstract][Full Text] [Related]
27. Fluorodeoxyglucose PET in the initial staging of germ cell tumours.
Hain SF; O'Doherty MJ; Timothy AR; Leslie MD; Partridge SE; Huddart RA
Eur J Nucl Med; 2000 May; 27(5):590-4. PubMed ID: 10853816
[TBL] [Abstract][Full Text] [Related]
28. Tumor markers and
Dondi F; Albano D; Bertagna F; Giubbini R
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2021; 40(5):287-292. PubMed ID: 34425969
[TBL] [Abstract][Full Text] [Related]
29. 18F-fluorodeoxyglucose positron emission tomography in evaluation of germ cell tumor after chemotherapy.
Johns Putra L; Lawrentschuk N; Ballok Z; Hannah A; Poon A; Tauro A; Davis ID; Hicks RJ; Bolton DM; Scott AM
Urology; 2004 Dec; 64(6):1202-7. PubMed ID: 15596197
[TBL] [Abstract][Full Text] [Related]
30.
Petrović J; Beatović S; Šobić-Šaranović D; Odalović S; Stojiljković M; Grozdic-Milojevic I; Veljkovic M; Jovanovic D; Artiko V
Hell J Nucl Med; 2022; 25(1):19-25. PubMed ID: 35388800
[TBL] [Abstract][Full Text] [Related]
31. Postchemotherapy retroperitoneal lymph node dissection (PC-RPLND) for seminoma: Limitations of surgical intervention after first-line chemotherapy.
Tachibana I; Alabd A; Whaley RD; McFadden J; Piroozi A; Hassoun R; Kern SQ; King J; Adra N; Rice KR; Foster RS; Einhorn LH; Cary C; Masterson TA
Urol Oncol; 2023 Sep; 41(9):394.e1-394.e6. PubMed ID: 37543446
[TBL] [Abstract][Full Text] [Related]
32. [Fluorodeoxyglucose (FDO) positron emission tomography (PET) in testicular germ cell tumors in adults: preliminary French clinical evaluation, development of the technique and its clinical applications].
Maszelin P; Lumbroso J; Theodore C; Foehrenbach H; Merlet P; Syrota A
Prog Urol; 2000 Dec; 10(6):1190-9. PubMed ID: 11217558
[TBL] [Abstract][Full Text] [Related]
33. Molecular Imaging for Evaluation of Viable Testicular Cancer Nodal Metastases.
Joice GA; Rowe SP; Gorin MA; Pierorazio PM
Curr Urol Rep; 2018 Nov; 19(12):110. PubMed ID: 30413968
[TBL] [Abstract][Full Text] [Related]
34. 18F-FDG PET/CT impact on testicular tumours clinical management.
Ambrosini V; Zucchini G; Nicolini S; Berselli A; Nanni C; Allegri V; Martoni A; Rubello D; Cricca A; Fanti S
Eur J Nucl Med Mol Imaging; 2014 Apr; 41(4):668-73. PubMed ID: 24265073
[TBL] [Abstract][Full Text] [Related]
35. The role of 18F-FDG PET/CT in the management of testicular cancers.
Cook GJ; Sohaib A; Huddart RA; Dearnaley DP; Horwich A; Chua S
Nucl Med Commun; 2015 Jul; 36(7):702-8. PubMed ID: 25757201
[TBL] [Abstract][Full Text] [Related]
36. Prognostic Role of Early Interim Fluorodeoxyglucose Positron Emission Tomography in Patients With Advanced Seminoma Undergoing Standard Treatment.
Raggi D; Bandini M; Giannatempo P; Farè E; Marandino L; Colecchia M; Calareso G; Padovano B; Serafini G; Alessi A; Necchi A
Clin Genitourin Cancer; 2021 Jun; 19(3):237-245.e2. PubMed ID: 32980271
[TBL] [Abstract][Full Text] [Related]
37. Significance of 18F-FDG PET/CT in Characterization of Equivocal Lesions in High-Risk Testicular Carcinoma in Restaging Setting.
Rasheed R; Al-Kandari F; Ghanem M; Marafi F; Usmani S
Asian Pac J Cancer Prev; 2020 Feb; 21(2):511-515. PubMed ID: 32102532
[TBL] [Abstract][Full Text] [Related]
38. Interim (18)F-Fluorodeoxyglucose Positron Emission Tomography for Early Metabolic Assessment of Response to Cisplatin, Etoposide, and Bleomycin Chemotherapy for Metastatic Seminoma: Clinical Value and Future Directions.
Necchi A; Nicolai N; Alessi A; Miceli R; Giannatempo P; Raggi D; Tana S; Serafini G; Padovano B; Mariani L; Crippa F; Salvioni R
Clin Genitourin Cancer; 2016 Jun; 14(3):249-54. PubMed ID: 26433626
[TBL] [Abstract][Full Text] [Related]
39. Prospective comparison of [18F]fluorodeoxyglucose positron emission tomography with conventional assessment by computed tomography scans and serum tumor markers for the evaluation of residual masses in patients with nonseminomatous germ cell carcinoma.
Kollmannsberger C; Oechsle K; Dohmen BM; Pfannenberg A; Bares R; Claussen CD; Kanz L; Bokemeyer C
Cancer; 2002 May; 94(9):2353-62. PubMed ID: 12015760
[TBL] [Abstract][Full Text] [Related]
40. False positive 2-(18)Fluroro-deoxy-D-glucose positron emission tomography (FDG-PET) in patients with disseminated seminoma and post-chemotherapy residual masses.
Wagner M; Bellmunt J; Boutros C; Bonardel G; Loriot Y; Albiges L; Massard C; Fizazi K
Clin Genitourin Cancer; 2013 Mar; 11(1):66-9. PubMed ID: 22981209
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]